Transcription
ExecutiveSummary–pgs.4- ‐9 Background–pgs.4- ‐6REMSDrugs–pgs.7- acies- ‐pgs.10- ‐52 AcariaHealth–pgs.10- ‐11AccredoHealth/CuraScript–pgs.12- ‐15AmberPharmacy–pgs.16- ‐17AvellaSpecialtyPharmacy–pgs.18- ‐19AxiumHealthcarePharmacy–pgs.20- ‐22BDIPharma–pgs.23- ‐25Biologics,Inc.–pgs.26- ‐29BioPlusSpecialtyPharmacy–pgs.30- ‐31BioRx–pgs.32- ‐33BriovaRx–pgs.34- ‐35CareMedPharmaceuticalServices–pgs.36- ‐37CommcarePharmacy–pgs.38- ‐39CoramRx–pgs.40- ‐41CurantHealth–pgs.42- ‐43CVSCaremark–pgs.44- ‐45CysticFibrosisServices–pgs.46- ‐47Diplomat–pgs.48- ‐50FFFEnterprises–pgs.51- ‐52
SpecialtyPharmacies- ‐pgs.53- ‐83 MedexBiocarePharmacy–pgs.53- s–pg.56OmnicareSpecialtyCareGroup–pgs.57- ‐59OncoSourceRx–pgs.60- ‐61Onco360- ‐pgs.62- s.67- ‐68PharmaHealthSpecialty–pgs.69- ‐70ReCeptPharmacy–pgs.71- veo 75- ‐76SmithMedicalPartners–pgs.77- ‐78TLCRx–pgs.79- ‐80TNHSpecialtyPharmacy–pgs.81- ‐82USBioservices–pg.83Sources–pg.84
ndwholesalers. stration(FDA)fordrugapproval. dhelpthemanufacturertrackinventory. commondrugsandmightrequireclosemonitoring. Forphysician- retailpharmacy.
asdevelopedin1972tolimitaccesstomethadone. dministration(FDA). roductoutweighitsrisks. elpprotectanexpensivedrugagainstrisk. manyREMSprogramsarerequiredbytheagency. mber17,2013.
llows: atientsClinicaldatareportingandanalysis aplanaroundtheuseofaspecialtypharmacy:Office- ‐administeredinjectableproductsClinic/office- ‐administeredinfusibleproductsSelf- ‐administeredinjectableproductsSelectoralagents tablecareorganizations
lgenePotiga/GSKProlia/AmgenPromacta/GSK
x/Auxilium
butionnetwork. oeson. ience. rsyoverthelastseveralyears. recentmergersandacquisitionsofthepayer- ertoprovideaccesstothesepayer- vespecialtypharmacyserviceprovider.
CenteneCorporationrecentlyacquiredAcariaHealthfor cariahealth.com6923LeeVistaBlvd,Suite300855- ‐422- ringnonpharmacologictherapiesandover- ‐the- �ects.ContactsDonHoward- ‐President&CEOSteveGranzyk- ‐VP,PharmaRelations&BusinessDevelopment
reimbursementassistanceprogrammanagementProtocol- stryprogramsFacilitationofmanufacturer- ‐sponsored,patient- ementStrategicconsultingWeb- ‐basedcollaborationReal- networkingHUBServicesParticipationinclinicaltrials
pts,Inc.314- ‐996- rsandpatients.ContactsGayleJohnston- rtin- ‐VPPharmaStrategiesandAccountManagement
agingsideeffects.Specialty- nursesprovidein- rapy- goingsupport,educationalmaterials,self- atedproductlinemanagerSupplies
lsMedicationwithsupplykitsAccesstoanon- disease- maskilledteamofexpertsFourdisease- ursementspecialists
Letairis ludingAccredo edthelaunchofpatientmanagementprogramsforSprycel sistentwithBMS’customer- withinBristol- ‐MyersSquibb.Nexplanon - g- ‐acting,progestin- ‐only,single- mberofspecialtypharmaciesincludingCuraScript.
Hy- 2ndStreet,SuiteA888- ‐370- ‐1724BackgroundHy- ‐VeeandAmberPharmacyhadbeenpartnersinHy- ‐VeePharmacySolutionssince2010.TheHy- ‐VeeacquisitionallowsHy- ntentsBillKaplan,Sr.- ‐ChiefExecutiveOfficerMichaelR.Agostino,R.Ph- tingapremilast,thefirstFDA- teswithpsoriasis.
/medication- ‐specificPromisesPrograms ilities.
2ndFloor623- ‐742- thstudytoassesstheeffectsofayear- Pharm.D.,FACA- sq.- pmanageanyside- ysaweek.
ertodispenseIMBRUVICA �zerforitsdrugInlyta (axitinib).Inlyta oritsdrugEYLEA r(wet)age- ementprogramsforSprycel sistentwithBMS’customer- withinBristol- ‐MyersSquibb.
Foundedin2000,Axium,awholly- chnologyParkBuilding407- ‐804- ayers.ContactsMarkMontgomer
Pomalyst/Celgene Potiga/GSK Prolia/Amgen Promacta/GSK Currently)ApprovedIndividualREMS: Product/Manufacturer Produ
